tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2013 Jan 1;9(1):115-21. doi: 10.4161/hv.22342.
Intanza (?) 9 ?g intradermal seasonal influenza vaccine for adults 18 to 59 years of age.
Leroux-Roels I, Weber F.
Source
Center for Vaccinology, Ghent University and Hospital; Ghent, Belgium.
Abstract
Seasonal influenza in healthy working-age adults accounts for a substantial part of the socioeconomic burden of this disease. Intanza? 9 ?g (sanofi pasteur) is a microneedle-delivered intradermal trivalent inactivated influenza vaccine approved in 2009 for the prevention of seasonal influenza in adults 18 to 59 years of age. The microneedle system reliably and reproducibly delivers the vaccine to the dermis. Clinical studies show that Intanza 9 ?g is as immunogenic and as well tolerated in working-age adults as a reference intramuscular trivalent inactivated vaccine. Local reactions to Intanza 9 ?g, mainly erythema, are transient, mostly mild or moderate, and do not affect acceptability. Intanza 9 ?g is considered satisfactory by at least 95% of both vaccinees and prescribers, especially because of the short needle and rapid administration. Because Intanza? 9 ?g offers an alternative to intramuscular vaccines, it might help increase influenza vaccine coverage rates.
PMID:
23442585
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/23442585
Intanza (?) 9 ?g intradermal seasonal influenza vaccine for adults 18 to 59 years of age.
Leroux-Roels I, Weber F.
Source
Center for Vaccinology, Ghent University and Hospital; Ghent, Belgium.
Abstract
Seasonal influenza in healthy working-age adults accounts for a substantial part of the socioeconomic burden of this disease. Intanza? 9 ?g (sanofi pasteur) is a microneedle-delivered intradermal trivalent inactivated influenza vaccine approved in 2009 for the prevention of seasonal influenza in adults 18 to 59 years of age. The microneedle system reliably and reproducibly delivers the vaccine to the dermis. Clinical studies show that Intanza 9 ?g is as immunogenic and as well tolerated in working-age adults as a reference intramuscular trivalent inactivated vaccine. Local reactions to Intanza 9 ?g, mainly erythema, are transient, mostly mild or moderate, and do not affect acceptability. Intanza 9 ?g is considered satisfactory by at least 95% of both vaccinees and prescribers, especially because of the short needle and rapid administration. Because Intanza? 9 ?g offers an alternative to intramuscular vaccines, it might help increase influenza vaccine coverage rates.
PMID:
23442585
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/23442585